Lifeforce’s micronized-progesterone page makes expansive statements about symptoms, mood and longer-term health. It also contains a more immediately practical piece of information: an allergy notice naming soy and/or peanuts. A reader asking about an oral capsule needs both the promise and that qualification read carefully, with the missing product details left visible.
This review, completed September 29, 2026, examines the specific progesterone page, menopause program and membership description. It does not assume that the product title establishes an oral capsule, a manufacturer or an approved formulation. The public records describe an assessment and treatment offering; they do not verify what would be prescribed or supplied to one person.
In this article
Micronized identifies something about the ingredient, not the whole product
The specific product page is titled Micronized Progesterone and describes prescription access through the service. The menopause page also lists progesterone among its treatments. These records establish relevant hormone care and a named ingredient offering.
The reviewed product text does not establish an exact dosage form, route, manufacturer or full label. It would therefore be premature to call it a verified Prometrium capsule. The medicine-role guide separates the intended purpose from product identity. A clinician or pharmacy needs to complete both parts of the description before a reader can meaningfully compare the proposed medicine with another preparation.
The allergy notice leaves an important formulation question
Lifeforce’s product notice says the product contains soy and/or peanut allergens. That wording should remain visible. It does not identify which ingredient or preparation accounts for each possibility, and it should not be rewritten as a guarantee that every offered version contains only one of them.
The capsule-excipients guide explains why a complete ingredient record matters. The actual proposed preparation, dispensing pharmacy and inactive ingredients need clarification. An alternative mentioned by a care team would require its own confirmation; it cannot be presumed allergen-free from the broad availability of alternatives. This review does not assess an individual allergy or recommend a substitution.
Its symptom promises are broader than a product label
The progesterone page describes near-complete symptom resolution and compares micronized progesterone favorably with synthetic progestins. It also makes brain, bone, mood and sleep claims. These are provider statements, not independently verified outcomes for the specific preparation that would be supplied.
The FDA Prometrium label illustrates a narrower record with defined indications, contraindications and cautions. Its evidence cannot simply be transferred to an unnamed Lifeforce formulation. Renew Youth’s review examines another broad progesterone-benefit discussion. The useful comparison asks about the actual medicine, use and evidence rather than treating a common ingredient name as support for every advertised outcome.
Two access-price descriptions remain unreconciled
The menopause landing page displays $99 a month. The progesterone product page, however, says pharmaceutical access requires a $149 monthly Lifeforce Membership, an eligible state, blood-test results and a clinician video consultation, plus a $599 Lifeforce Diagnostic purchase. These are different published descriptions, not a single verified checkout.
This review cannot establish which arrangement would apply to the reader or whether one page supersedes the other. Neither page supplies a confirmed price for an individual progesterone preparation. Fountain’s review provides a useful comparison with explicit longer billing periods. A clear quote should resolve the actual access plan before medicine costs are compared.
Testing descriptions also need to belong to one selected plan
The menopause page opens with eleven-plus biomarkers and three tests in the first year, then two afterward. Elsewhere it describes fifty-plus biomarkers and quarterly retesting. The general membership page also advertises recurring blood draws and clinician consultations. Those differences may concern different program components, but the public wording does not reconcile them for an individual purchase.
A testing cadence describes a service, not an instruction for personal monitoring. The follow-up guide supports asking which tests are included, what decision they inform and who interprets them. More measurements do not by themselves establish the identity or benefit of a particular progesterone medicine.
A sleep goal still needs specific safety counseling
The product page promotes mood and sleep effects. That does not make unwanted drowsiness a desirable result. The drowsiness questions guide identifies practical concerns to discuss without diagnosing a reaction or suggesting a change in timing.
For the exact Prometrium product, the FDA label warns about dizziness and drowsiness and caution around driving or machinery. This is evidence for asking about the actual preparation’s effects, not proof that Lifeforce supplies that product. The prescriber should distinguish the desired clinical outcome from effects that interfere with ordinary activities and explain how concerns will be assessed.
A complete proposal would replace several uncertainties with names
The membership description promises clinician and coaching support. Those roles should be clear when the question concerns a prescribed medicine rather than general wellbeing. A coach’s availability does not identify the professional responsible for a formulation decision or a pharmacist’s ingredient answer.
The remaining questions are concrete: which preparation and route, for what purpose, through which pharmacy, under which financial arrangement? Lifeforce’s published records justify a service assessment, but they do not answer all of those questions. This review leaves the unresolved points open rather than merging conflicting pages into an attractive capsule price or treating a broad benefit claim as an individual clinical recommendation.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Lifeforce: Micronized ProgesteroneProvider product description, soy/peanut allergy notice and access terms; exact oral capsule, manufacturer and complete excipients not established · Checked 2026-09-29
- Lifeforce: Menopause ManagementProvider menopause service and plan descriptions; different membership and testing statements remain unreconciled · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- Lifeforce: Become a memberProvider recurring membership services and support roles; not a personal testing schedule or capsule price · Checked 2026-09-29